Cargando…

G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes

BACKGROUND: Granzyme B is a key effector of cytotoxic T lymphocytes (CTLs), and its expression level positively correlates with the response of patients with mesothelioma to immune checkpoint inhibitor immunotherapy. Whether metabolic pathways regulate Gzmb expression in CTLs is incompletely underst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Chunwan, Yang, Dafeng, Klement, John D, Colson, Yolonda L, Oberlies, Nicholas H, Pearce, Cedric J, Colby, Aaron H, Grinstaff, Mark W, Ding, Han-Fei, Shi, Huidong, Liu, Kebin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753452/ https://www.ncbi.nlm.nih.gov/pubmed/35017152 http://dx.doi.org/10.1136/jitc-2021-003543

Ejemplares similares

H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth
por: Lu, Chunwan, et al.
Publicado: (2022)

Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells
por: Lu, Chunwan, et al.
Publicado: (2018)

Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
por: Lu, Chunwan, et al.
Publicado: (2019)

Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression
por: Klement, John D., et al.
Publicado: (2021)

p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
por: Lu, Chunwan, et al.
Publicado: (2020)

WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
por: Lu, Chunwan, et al.
Publicado: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer
por: De Sanctis, Francesco, et al.
Publicado: (2022)

Pilot-scale production of expansile nanoparticles: Practical methods for clinical scale-up
por: Colby, Aaron H., et al.
Publicado: (2021)

IRF8 Regulates Intrinsic Ferroptosis through Repressing p53 Expression to Maintain Tumor Cell Sensitivity to Cytotoxic T Lymphocytes
por: Poschel, Dakota B., et al.
Publicado: (2023)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer
por: Quan, Yibo, et al.
Publicado: (2023)

T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins
por: Schlichtner, Stephanie, et al.
Publicado: (2023)

Granzyme B; the chalk-mark of a cytotoxic lymphocyte
por: Waterhouse, Nigel J, et al.
Publicado: (2004)

Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles
por: Colby, Aaron H., et al.
Publicado: (2016)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

5-Fluorouracil Suppresses Colon Tumor through Activating the p53-Fas Pathway to Sensitize Myeloid-Derived Suppressor Cells to FasL(+) Cytotoxic T Lymphocyte Cytotoxicity
por: Yang, Yingcui, et al.
Publicado: (2023)

Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
por: Lv, Tingting, et al.
Publicado: (2022)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Cellular cytotoxicity is a form of immunogenic cell death
por: Minute, Luna, et al.
Publicado: (2020)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
por: Renga, Giorgia, et al.
Publicado: (2022)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
por: Pani, Fabiana, et al.
Publicado: (2022)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
por: Peng, Zhi-Peng, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021)

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells
por: Sun, Yi, et al.
Publicado: (2021)

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
por: Simonds, Erin F, et al.
Publicado: (2021)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oakn67d2u4e1ujk7i5h8ij98uk